The Copenhagen Actinic Keratosis Study (COAKS). A decentralised clinical trial to evaluate tolerability, safety and efficacy of daily field-directed topical treatment with cytosolic phospholipase A(2) inhibitor, AVX001, in participants with actinic keratosis: protocol for a randomised controlled phase I/IIa trial

INTRODUCTION: Actinic keratosis (AK) is the most common precancerous skin condition caused by long-term UV exposure. Given the high recurrence rate of 15%–53%, identifying safe and effective treatment options is warranted. AVX001, a cytosolic phospholipase A(2)α (cPLA(2)α) enzyme inhibitor, is a nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortner, Vinzent Kevin, Johansen, Berit, Kilov, Kim, Castillo Mondragón, Alejandro, Duvold, Tore, Kihl, Jesper, Ashcroft, Felicity J, Feuerherm, Astrid J, Pind Laugesen, Charlotte, Marcker Espersen, Maiken Lise, Manole, Ionela, Isberg, Ari Pall, Andersen, Anders Daniel, Rakvaag, Elin, Zibert, John R, Haedersdal, Merete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535213/
https://www.ncbi.nlm.nih.gov/pubmed/36198452
http://dx.doi.org/10.1136/bmjopen-2022-061012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535213/
https://www.ncbi.nlm.nih.gov/pubmed/36198452
http://dx.doi.org/10.1136/bmjopen-2022-061012

Ejemplares similares